KP
Kaveri Pohlman Clear Street Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
ArriVent BioPharma
AVBP
$800M
| $19.72 | $32 |
62%
upside
| Buy |
25 Jun ‘25
2 months ago |
|
2
Genmab
GMAB
$17.1B
| $27.80 | $47 |
69%
upside
| Buy |
27 Jun ‘24
1 year ago |
|
3
Cullinan Oncology
CGEM
$405M
| $6.86 | $30 |
337%
upside
| Buy |
17 Apr ‘24
1 year ago |
|
4
Xencor
XNCR
$593M
| $8.32 | $38 |
357%
upside
| Buy |
16 Apr ‘24
1 year ago |
|
5
Nuvation Bio
NUVB
$1.15B
| $3.37 | $5 |
48%
upside
| Buy |
26 Mar ‘24
1 year ago |
|
6
Janux Therapeutics
JANX
$1.46B
| $24.32 | $62 |
155%
upside
| Buy |
21 Mar ‘24
1 year ago |
|
7
Pyxis Oncology
PYXS
$115M
| $1.85 | $8 |
332%
upside
| Buy |
9 Feb ‘24
1 year ago |
|
8
Exelixis
EXEL
$10.2B
| $37.88 | $27 |
29%
downside
| Buy |
19 Dec ‘23
1 year ago |
|
9
Arcus Biosciences
RCUS
$1.2B
| $11.25 | $70 |
522%
upside
| Buy |
23 Aug ‘23
2 years ago |
|
10
Shattuck Labs
STTK
$92M
| $1.92 | $12 |
525%
upside
| Buy |
31 Aug ‘22
3 years ago |
|
11
CytomX Therapeutics
CTMX
$343M
| $2.08 | $8 |
285%
upside
| Buy |
7 Jul ‘22
3 years ago |
|
12
Sonnet BioTherapeutics
SONN
$23.1M
| $3.38 | $4,928 |
145,699%
upside
| Buy |
9 Feb ‘22
3 years ago |
|